ClinicalTrials.gg
CompletedNCT06048536Updated Nov 29, 2024

Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch

A Phase 2 interventional study of MR-130A-01 Transdermal patch and MR-130A-01 Transdermal patch in Contraception, sponsored by Mylan Pharmaceuticals Inc. Completed at 1 site in Germany. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

A single-center, randomized, open-label, parallel-group, multi-arm, phase II clinical trial in healthy women aged 18 to 35 years who have a documented ovulatory cycle prior to randomization.

Read the detailed description

MR-130A-01 is a progestin-only TDS containing NGMN as its progestin. NGMN is currently available in combination with EE in CHC TDSs Xulane® (US) and Evra® (EU), at doses of 150 mcg/day (Xulane® USPI 2022) and 203 mcg/day (Evra®SmPC 2022) respectively. In the currently planned dose-finding clinical trial the ovulation inhibition and the impact on further physiological functions and hormones of the three dose strengths of MR-130A-01 will be investigated in healthy pre-menopausal obese and non-obese women with ovulatory menstrual cycles. Eligible subjects will be randomized according to their body mass index (BMI) into one of 7 treatment arms with different doses and regimens of IMP administration. The IMPs which are transdermal patches, will be applied to the skin (upper outer arm, abdomen, buttock or back) and will be changed weekly. Depending on the treatment arm, either 4 or 3 patches of an allocated patch strength will be applied per cycle (28/0-day regimen and 21/7-day regimen). Patch adhesion will be assessed by the subjects daily and the results (adhesion scores) will be recorded in a diary. Throughout the clinical trial, ovarian activity will be monitored by TVUS, and blood samples will be collected for determination of progesterone (P), estradiol (E2), LH and FSH concentrations. The inhibition of ovulation will be assessed by Hoogland and Skouby Score (HSS). In addition, bleeding pattern will be assessed based on the subject's records of bleeding and its intensity in a diary.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Mylan Pharmaceuticals Inc is the lead sponsor of 160 studies on the registry; 1 is open to participants now.

First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, post-menarcheal and premenopausal women of age 18 to 35 years inclusive).
  2. ≥18.0 kg/m2 at screening examination.
  3. Subjects must be in good physical and mental health as determined by vital signs, medical history, and physical and gynecological examination, as assessed by the investigator.
  4. Written , after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subject participating in the clinical trial.
  5. Status at least 3 months after a delivery, abortion, and stopping lactation, if applicable, before screening.
  6. Has regular menstrual cycles that are between 21 and 35 days in duration as reported by the subject during anamnesis, with an intact uterus and ovaries. If the subject uses hormonal at screening, historic data should be used to evaluate this criterion.
  7. Both ovaries must be visible on TVUS examination during screening.
  8. Ovulatory pre-treatment cycle, as confirmed by a progesterone concentration >10.0 nmol/L.
  9. Subjects must consent to use reliable non-hormonal contraceptive methods (male condoms, diaphragm, or heterosexual abstinence) throughout the study, unless the subject has a history of female sterilization or sterilization of the sexual partner.

Exclusion criteria

Exclusion Criteria:

  1. Known or intolerance to any ingredient of the product.
  2. History or presence of dermal sensitivity to medicated patches or to topical applications including bandages, surgical tape.
  3. Pregnancy or a positive serum beta human chorionic gonadotropin (β-hCG) pregnancy test at screening.
  4. abnormal findings from serum biochemistry and hematology and and virus/ (HIV) serology as evaluated by the investigator.
  5. ASAT (aspartate-aminotransferase) > 20 % (ULN), ALAT (alanine-aminotransferase) > 10 % ULN, > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL corresponds to > 9 μmol/l ULN).
  6. Use of a non-hormonal intra-uterine device within the pre-treatment cycle or any hormonal as follows:

    • Short-acting hormonal contraceptives such as oral, patch, ring or intra-uterine systems within the menstrual cycle prior to the pre-treatment cycle.
    • Injectable (intramuscularly or subcutaneously) within 10 months (three-month treatment duration), 6 months (two-month treatment duration) or 3 months (one-month treatment duration) prior to the start of pre-treatment cycle or implants within the menstrual cycle prior to the pre-treatment cycle.
  7. Known or suspected or history thereof.
  8. Has unexplained vaginal bleeding within the past 6 months suspicious for serious condition, or any abnormal bleeding which is expected to recur during the study (eg. bleeding from cervical polyp, recurrent bleeding after sex).
  9. History or presence of ischemic heart disease, coronary artery disease, myocardial infarction, stroke, other cerebrovascular diseases including (TIAs).
  10. Known dyslipidemias with other known cardiovascular risk factors.
  11. History or presence of hypertension (including adequately controlled hypertension) or hypertension with vascular disease or elevated blood pressure (BP) defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, measured in sitting position after at least 5 minutes of rest (a single reading of blood pressure level is not sufficient to classify a woman as hypertensive).
  12. Pulse rate \< 50 bpm or > 90 bpm
  13. Presence of deep vein thrombosis/pulmonary embolism.
  14. Has any comorbid condition that may require major surgery with prolonged immobilization during the study period.
  15. History or presence of migraine with aura.
  16. Presence of liver disease including severe (decompensated) cirrhosis, benign (e.g., hepatocellular adenoma) or malignant liver tumors.
  17. Chronic disease potentially necessitating organ transplantation during the anticipated course of the study.
  18. Subjects having any other known to progestin only contraception as defined by category 3 or 4 conditions per World Health Organization Medical eligibility
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Norelgestromin low dose 2.43mg 28/0 regimen non-Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin mid dose 3.64mg 28/0 regimen non-Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin high dose 4.86mg 28/0 regimen non-Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin high dose 4.86mg 21/7 regimen non-Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin mid dose 3.64mg 28/0 regimen Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin high dose 4.86mg 28/0 regimen Obese

    Drug: MR-130A-01 Transdermal patch

  • Experimental
    Norelgestromin high dose 4.86mg 21/7 regimen Obese

    Drug: MR-130A-01 Transdermal patch

Interventions

  • DrugMR-130A-01 Transdermal patch

    MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

  • DrugMR-130A-01 Transdermal patch

    MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

  • DrugMR-130A-01 Transdermal patch

    MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period

  • DrugMR-130A-01 Transdermal patch

    MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.

06

What researchers measure

Primary outcomes

  1. Proportion of responder overall (subjects with no ovulation in both treatment cycles)

    A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.

    Time frame: 56 days

  2. Proportion of responder in cycle (subjects with no ovulation in one of the treatment cycles)

    A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.

    Time frame: 56 days

Secondary outcomes

  1. For assessment of ovarian activity, Hoogland and Skouby score frequency analysis will be provided for:

    * Subjects with either HSS 5 or 6 * Subjects with HSS \<5 * Subjects for each HSS from 1 to 6 * Subjects with HSS 5 or 6 and positive Landgren criterion * Subjects with HSS 5 or 6 and negative Landgren criterion. Frequency analysis will be provided per treatment arm for each of the treatment cycles.

    Time frame: 56 days

  2. Corpus luteum function will be evaluated in subjects by using Landgren criteria in conjunction with Hoogland and Skouby score. Frequency analysis will be provided for:

    * Subjects with HSS 5 or 6 and positive Landgren criterion * Subjects with HSS 5 or 6 and negative Landgren criterion. Frequency analysis will be provided per treatment arm for each of the treatment cycles. Furthermore, frequency of occurrence of any Landgren criterion over both cycles will be calculated.

    Time frame: 56 days

  3. The diameter of the largest FLS in both the right and left ovary will be measured (for each, the mean diameter from two directions). The largest of all follicles is considered the dominant FLS (FLSdom) for that study day.

    From this, the subject-wise maximum FLS diameter (MFD) will be calculated separately for each treatment cycle and over both cycles. The maximum endometrial thickness (ETmax) subject-wise will be calculated for each treatment cycle and for the entire treatment period using transvaginal ultrasound. This will be reported per visit and for each of the treatment cycles

    Time frame: 56 days

  4. The effect of cervical mucus will be calculated by Insler score. The subject-wise maximum Insler score (ISmax) will be calculated for each treatment cycle and for the entire treatment period.

    Time frame: 56 days

  5. To assess the effects of MR-130A-01 on sexual hormones(estradiol [E2], progesterone [P]) hormone concentrations determined in serum

    Descriptive statistics will be given per treatment arm for: Concentrations of FSH, LH, E2, and P at each visit • Max FSH, max LH, max E2, mean E2, max P in each treatment cycle and over both cycles

    Time frame: 56 days

  6. Steady state concentration of NGMN and norgestrel will be calculated per treatment arm by means of non-compartmental analysis.

    Descriptive statistics (N, arithmetic means, SD, medians, minimum, maximum geometric means, geometric CV) will be presented for all pharmacokinetic parameters, separately for each treatment and analyte.

    Time frame: 56 days

  7. Patch adhesion will be evaluated by both data subject diary and site personnel.

    Frequency analysis of patch adhesion scores will be provided per treatment arm * For each day of the application period of one patch (Day 1 to Day 7) * For the subject-wise mean and maximum application score over the entire application period of one patch (1 week). In addition, the following evaluations will be presented per treatment arm for each evaluation time-point (day/week): * Proportion of subjects achieving greater than 90% adherence (score 0) * Proportion of subjects with a meaningful degree of detachment (patch detachment ≥25% (estimated score ≥2) * Number of patches that are completely detached (score 4).

    Time frame: 56 days

  8. Safety will be evaluated by TEAEs considering action taken, frequency, seriousness, intensity, relationship to the IMP, outcome as well as treatment.

    Evaluation will be described by absolute and relative frequency. Tolerability will be evaluated by application site reactions. Frequency analysis of skin irritation categories will be provided per treatment arm over the entire treatment period.

    Time frame: 56 days

  9. Bleeding pattern will be assessed in each single subject over treatment cycle 1 and treatment cycle 2 (defined as 56-day reference period) by

    * Incidences (percentage of subjects) of unscheduled/scheduled bleeding and/or spotting episodes within the reference period * The mean, median and range of number of observed days of bleeding and/or spotting within the reference period * The observed days of bleeding and/or spotting within the reference period presented as total days, unscheduled days and scheduled days for bleeding and/or spotting, bleeding only and spotting only * Incidences (percentage of subjects) of complete absence of bleeding or spotting during the reference period.

    Time frame: 56 days

07

Study locations

1 site
  • dinox GmbH
    Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Sep 21, 2023
StartActual
Dec 22, 2023
Primary completionActual
Jan 18, 2024
CompletionActual
Jan 18, 2024
Results delay requested
Nov 26, 2024
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06048536
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Dec 22, 2023
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024
Last update
Nov 29, 2024

Study contacts

Sandeep Jagtap
study director · Mylan Pharmaceuticals Private Limited (A Viatris Company)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion